- ‘’SARS-COV-2 Virüsüne Karşı Koruyucu Pastil/Çiğneme Tableti’’ Patent Başvuru numarası TR 2022/000292’.
- “Selecting recombinant antibody used in pharmaceutical composition for inhibiting angiogenesis in angiogenesis-related diseases, by obtaining recombinant antibodies that block vascular endothelial growth factor receptor 2 activity” Patent Number(s): WO2012004631-A2; WO2012004631-A3; EP2591002-A2; CN103119063-A; JP2013540420-W; KR2013132739-A; US2014199301-A1 Inventor(s): BALCIOGLU B K, OZDEMIR BAHADIR A, BAHAR A, BAYSAL K, SERHATLI M, KACAR O, KILIC T, AKGUN E, OZKAN A, ERDAG B, OZDEMIR B A, AKGUEN E, OEZKAN A. Patent Assignee Name(s) and Code(s): TUBITAK (TUBI-Non-standard), TUBITAK (TUBI-Non-standard), TUBITAK-SCI & TECHNOLOGICAL RES COUNCIL (TUBI-Non-standard), TUBITAK (TUBI-Non-standard), Derwent Primary Accession Number: 2012-A79078 [47].
- “Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (VEGFR—2/KDR)” Berrin Erdağ, Bertan Koray Balcioğlu, Aylin Ozdemir Bahadir, Aydin Bahar, Kemal Baysal, Müge Serhatli, Ömer Kaçar, Türker Kılıç, Emel Akgün, Abdulkadir Özkan; US, 2015/11/24; Patent Number(s): 9193792.
